Pathogenetic aspects and current trends in the treatment of benign breast dysplasia

DOI

https://dx.doi.org/10.18565/aig.2025.21

Yureneva S.V., Averkova V.G., Ashrafyan L.A.
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia

Benign breast dysplasia is the most common breast pathology affecting up to 50% of the female population. According to experts from the World Health Organization, benign breast dysplasia is caused by an impaired ratio of epithelial and connective tissue components of the breast tissue and its proliferative changes. The presence of benign breast dysplasia on average doubles the risk of developing breast cancer. Benign breast dysplasia and breast cancer have common risk factors and similar molecular mechanisms of development; therefore, active detection and pathogenetic treatment of benign breast dysplasia is part of the strategy for the prevention of breast cancer. The article presents a review of the current literature data on the pathogenetic mechanisms of benign breast dysplasia and its progression, and reflects the significance of their influence on modifiable risk factors of breast cancer and treatment of benign breast dysplasia. The review discusses current hormonal and non-hormonal conservative therapy for benign breast dysplasia and strategies for cancer prevention.
Conclusion: Benign breast dysplasia should be treated regardless of the clinical manifestations of the disease. In case of patient’s complaints, therapy for benign breast dysplasia should be administered to improve the patient’s general well-being and the clinical picture of the disease, which in turn should improve the patient’s quality of life. In addition to the above objectives, pathogenetic therapy should be considered as a strategy to prevent carcinogenesis in breast tissue.

Authors’ contributions: Yureneva S.V., Ashrafyan L.A. – developing the concept of the study; Averkova V.G. – collecting and processing the material, writing the text; Yureneva S.V. – editing the article.
Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Yureneva S.V., Averkova V.G., Ashrafyan L.A. Pathogenetic aspects and current trends in the treatment of benign breast dysplasia.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (2): 130-135 (in Russian)
https://dx.doi.org/10.18565/aig.2025.21

benign breast dysplasia

mastalgia

breast cancer

Full text (in Russian)

Министерство здравоохранения Российской Федерации. Клинические рекомендации. Доброкачественная дисплазия молочной железы. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Benign breast dysplasia. 2024. (in Russian)].
Salamat F., Niakan B., Keshtkar A., Rafiei E., Zendehdel M. Subtypes of benign breast disease as a risk factor of breast cancer: a systematic review and meta analyses. Iran J. Med. Sci. 2018; 43(4): 355-64.
Faguy K. Fibrocystic breast changes. Radiol. Technol. 2022; 93(3): 303M-315M.
Адамян Л.В., Родионов В.В., Шешко Е.Л., Долгушина Н.В. Доброкачественная дисплазия молочной железы с позиции BI-RADS: современный взгляд на проблему. Проблемы репродукции. 2023; 29(5): 119-24. [Adamyan L.V., Rodionov V.V., Sheshko E.L., Dolgushina N.V. Benign breast dysplasia from the perspective of BI-RADS: a modern view of the problem. Russian Journal of Human Reproduction. 2023; 29(5): 119 24. (in Russian)]. https://dx.doi.org/10.17116/repro202329051119.
Ашрафян Л.А., Бабаева Н.А., Антонова И.Б., Алешикова О.И., Герфанова Е.В. Значение эстрогенных метаболитов в канцерогенезе опухолей женской репродуктивной системы. Медицинский оппонент. 2019; 3(7): 34-9. [Ashrafyan L.A., Babaeva N.A., Antonova I.B., Aleshikova O.I., Gerfanova E.V. The role of hormonal disbalance in the carcinogenesis of tumors of the female reproductive system. Medical opponent. 2019; 3(7): 34-9. (in Russian)].
Ашрафян Л.А., Бабаева Н.А., Антонова И.Б., Овчинникова О.А., Алешикова О.И., Моцкобили Т.А., Кузнецов И.Н. Уровень баланса эстрогенных метаболитов при раке молочной железы и пути его коррекции. Опухоли женской репродуктивной системы. 2015; 11(3): 22-9. [Ashrafyan L.A., Babaeva N.A., Antonova I.B., Ovchinnikova O.A., Aleshikova O.I., Motskobili T.A., Kuznetsov I.N. The balance of estrogen metabolites in breast cancer and the ways of its correction. Tumors of female reproductive system. 2015; 11(3): 22-9. (in Russian)]. https://dx.doi.org/10.17650/1994-4098-2015-11-3-22-29.
Graham J., Fallah-Rad N., Kolinsky M., Morgan S., Shayegan B. 2024 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium Meeting highlights. Can. Urol. Assoc. J. 2024; 18(5): E179-E186. https://dx.doi.org/10.5489/cuaj.8797.
Gradishar W.J., Moran M.S., Abraham J., Abramson V., Aft R., Agnese D. et al. Breast cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2024; 22(5): 331-57. https://dx.doi.org/10.6004/jnccn.2024.0035.
Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71(3): 209-49. https://dx.doi.org/10.3322/caac.21660.
Coles C.E., Earl H., Anderson B.O., Barrios C.H., Bienz M., Bliss J.M. et al.; Lancet Breast Cancer Commission. The Lancet Breast Cancer Commission. Lancet. 2024; 403(10439): 1895-950. https://dx.doi.org/10.1016/S0140-6736(24)00747-5.
Xu Y., Gong M., Wang Y., Yang Y., Liu S., Zeng Q. Global trends and forecasts of breast cancer incidence and deaths. Sci. Data. 2023; 10(1): 334. https://dx.doi.org/10.1038/s41597-023-02253-5.
Worsham M.J., Abrams J., Raju U., Kapke A., Lu M., Cheng J. et al. Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J. 2007; 13(2): 115-21. https://dx.doi.org/10.1111/j.1524-4741.2007.00388.x.
Castells X., Domingo L., Corominas J.M., Torá-Rocamora I., Quintana M.J., Baré M. et al. Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. Breast Cancer Res. Treat. 2015; 149(1): 237-44. https://dx.doi.org/10.1007/s10549-014-3208-z.
Román M., Louro J., Posso M., Alcántara R., Peñalva L., Sala M. et al. Breast density, benign breast disease, and risk of breast cancer over time. Eur. Radiol. 2021; 31(7): 4839-47. https://dx.doi.org/10.1007/s00330-020-07490-5.
Dyrstad S.W., Yan Y., Fowler A.M., Colditz G.A. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res. Treat. 2015; 149(3): 569-75. https://dx.doi.org/10.1007/s10549-014-3254-6.
Lou Z., Li Y., Yang Y., Wang L., Yang J. Affects of anxiety and depression on health-related quality of life among patients with benign breast lumps diagnosed via ultrasonography in China. Int. J. Environ. Res. Public Health. 2015; 12(9): 10587-601. https://dx.doi.org/10.3390/ijerph120910587.
Каприн А.Д., Рожкова Н.И., ред. Мастопатии. М.: ГЭОТАР-Медиа; 2019. 320 с. [Kaprin A.D., Rozhkova N.I., ed. Mastopathia. Moscow: GEOTAR-Media; 2019. 320 p. (in Russian)].
Dong C., Yuan T., Wu Y., Wang Y., Fan T.W., Miriyala S. et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013; 23(3): 316-31. https://dx.doi.org/10.1016/j.ccr.2013.01.022.
Муйжнек Е.Л., Киселев В.И., Рожкова Н.И., Ашрафян Л.А. Между мастопатией и раком молочной железы: факторы риска и патогенетическое лечение. М.: ГЭОТАР-Медиа; 2024: 33. [Muizhnek E.L., Kiselev V.I., Rozhkova N.I., Ashrafyan L.A. Between mastopathy and breast cancer: risk factors and pathogenetic treatment. Moscow: GEOTAR-Media; 2024: 33. (in Russian)].
Mubarik S., Liu X., Malik S.S., Wang L., Yu Y., Yu C. Evaluation of lifestyle risk factor differences in global patterns of breast cancer mortality and DALYs during 1990-2017 using hierarchical age-period-cohort analysis. Environ. Sci. Pollut. Res. Int. 2021; 28(36): 49864-76. https://dx.doi.org/10.1007/s11356-021-14165-1.
Yiangou K., Mavaddat N., Dennis J., Zanti M., Wang Q., Bolla M.K. et al. Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction. Breast Cancer Res. 2024; 26(1): 189. https://dx.doi.org/10.1186/s13058-024-01947-x.
Fanfarillo F., Caronti B., Lucarelli M., Francati S., Tarani L., Ceccanti M. et al. Alcohol consumption and breast and ovarian cancer development: molecular pathways and mechanisms. Curr. Issues Mol. Biol. 2024; 46(12): 14438-52. https://dx.doi.org/10.3390/cimb46120866.
Premenopausal Breast Cancer Collaborative Group; Schoemaker M.J., Nichols H.B., Wright L.B., Brook M.N., Jones M.E., O'Brien K.M. et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 2018; 4(11): e181771. https://dx.doi.org/10.1001/jamaoncol.2018.1771.
Bodewes F.T.H., van Asselt A.A., Dorrius M.D., Greuter M.J.W., de Bock G.H. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. Breast. 2022; 66: 62-8. https://dx.doi.org/10.1016/j.breast.2022.09.007.
Шабаев Р.М., Колядина И.В., Благовестнов Д.А., Староконь П.М. Факторы риска развития рака молочной железы на фоне длительного течения доброкачественных заболеваний молочной железы: 10-летнее наблюдательное исследование. Опухоли женской репродуктивной системы 2024; 20(1): 31-8. [Shabaev R.M., Kolyadina I.V., Blagovestnov D.A., Starokon P.M. Risk factors for breast cancer in patients with benign breast diseases: a 10-year observational study. Tumors of Female Reproductive System. 2024; 20(1): 31-8. (in Russian)]. https://dx.doi.org/10.17650/1994-4098-2024-20-1-31-38.
Sharma A.A., Kumar A., Pasi D.K., Dhamija P., Garry G.K., Saini A. et al. Mastalgia - the burden beneath. Eur. J. Breast Health. 2023; 20(1): 15-8. https://dx.doi.org/10.4274/ejbh.galenos.2023.2023-3-10.
Sherman M.E., Vierkant R.A., Masters M., Radisky D.C., Winham S.J., Degnim A.C. et al. Benign breast disease, NSAIDs, and postmenopausal breast cancer risk in the CPS-II cohort. Cancer Prev. Res. (Phila). 2023; 16(3): 175-84. https://dx.doi.org/10.1158/1940-6207.CAPR-22-0403.
Прилепская В.Н., Ледина А.В. Применение гомеопатических препаратов для лечения масталгии и мастопатии. Лечащий врач. 2012; 11. [Prilepskaya V.N., Ledina A.V. Use of homeopathic medications for mastalgia and mastopathy treatment. The Lechaschi Vrach Journal. 2012; (11). (in Russian)].
Прилепская В.Н. и соавт. Отчет о результатах клинического исследования комплексного гомеопатического препарата «Мастопол» у больных с фиброзно-кистозной болезнью молочных желез. М.; 2005. 10 с. [Prilepskaya V.N. et al. Report on the results of a clinical study of the complex homeopathic product Mastopol in patients with fibrocystic breast disease. Moscow; 2005. 10 p. (in Russian)].
Ледина А.В., Прилепская В.Н. Масталгия. Лечение экстрактом Vitex agnus castus. Доктор.Ру. 2012; 1(69): 13-9. [Ledina A.V., Prilepskaya V.N. Mastalgia: Treatment with Vitex agnus castus extract. Doctor.Ru. 2012; 1(69): 13-9. (in Russian)].
Mirzaee F., Fakari F.R., Babakhanian M., Roozbeh N., Ghazanfarpour M. The effectiveness of herbal medicines on cyclic mastalgia: a systematic review on meta-analysis. Rev. Bras. Ginecol. Obstet. 2022; 44(10): 972-85. https://dx.doi.org/10.1055/s-0042-1755456.
Höller M., Steindl H., Abramov-Sommariva D., Kleemann J., Loleit A., Abels C. et al. Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study. Arch. Gynecol. Obstet. 2024; 309(5): 2089-98. https://dx.doi.org/10.1007/s00404-023-07363-4.
Андреева Е.Н., Рожкова Н.И. Эффективность трансдермального геля, содержащего микронизированный прогестерон, в лечении фиброзно-кистозной мастопатии. Результаты российского исследования. Акушерство и гинекология. 2016; 12: 131-6. [Andreeva E.N., Rozhkova N.I. Efficacy of micronized progesterone-containing transdermal gel in the treatment of fibrocystic mastopathy: Results of a Russian study. Obstetrics and Gynecology. 2016; (12): 131-6. (in Russian)]. https://dx.doi.org/10.18565/aig.2016.12.131-6.
Chang K.J., Lee T.T., Linares-Cruz G., Fournier S., de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil. Steril. 1995; 63(4): 785-91.
Brkic M., Vujovic S., Ivanisevic M.F., Ivovic M., Gajic M.T., Marina L. et al. The influence of progesterone gel therapy in the treatment of fibrocystic breast disease. Open Journal of Obstetrics and Gynecology. 2016; 6(5): 334-41. https://dx.doi.org/10.4236/ojog.2016.65042.
Протасова А.Э., Андреева Е.Н., Рожкова Н.И., Вандеева Е.Н. Динамика клинических симптомов фиброзно–кистозной мастопатии на фоне трансдермального геля микронизированного прогестерона: результаты российского многоцентрового наблюдательного исследования БРЕСТ. Акушерство и гинекология. 2018; 11: 138-44. [Protasova A.E., Andreeva E.N., Rozhkova N.I., Vandeeva E.N. Dynamics of clinical symptoms of fibrocystic breast disease in the course of monotherapy with transdermal gel of micronized progesterone: results of the russian multicenter observational study BREAST. Obstetrics and Gynecology. 2018; (11): 138-44. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.11.138-144.
Протасова А.Э. Динамика клинических симптомов фиброзно-кистозной мастопатии на фоне монотерапии препаратом трансдермального микронизированного прогестерона: результаты многоцентрового когортного исследования БРЕСТ-2. Акушерство и гинекология. 2020; 8: 159-68. [Protasova A.E. Changes in the clinical symptoms of fibrocystic mastopathy during monotherapy with transdermal micronized progesterone: results of the BREAST-2 multicenter open prospective cohort study. Obstetrics and Gynecology. 2020; (8): 159-68 (in Russian)]. https://dx.doi.org/10.18565/aig.2020.8.159-168.
Sinha M.K., Barman A., Sahu S., Jha A.K., Asharaf A.A. Tamoxifen in Mastalgia: A meta-analysis. J. Obstet. Gynaecol. Can. 2022; 44(10): 1084-94. https://dx.doi.org/10.1016/j.jogc.2022.06.006.
Horner N.K., Lampe J.W. Potential mechanisms of diet therapy for fibrocystic breast conditions show inadequate evidence of effectiveness. J. Am. Diet. Assoc. 2000; 100(11): 1368-80. https://dx.doi.org/10.1016/S0002-8223(00)00383-7.
Mansel R.E., Das T., Baggs G.E., Noss M.J., Jennings W.P., Cohen J. et al. A randomized controlled multicenter trial of an investigational liquid nutritional formula in women with cyclic breast pain associated with fibrocystic breast changes. J. Womens Health (Larchmt). 2018; 27(3): 333-40. https://dx.doi.org/10.1089/jwh.2017.6406.
Alipour S., Rastad H., Saberi A., Faiz F., Maleki-Hajiagha A., Abedi M. Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial. Daru. 2021; 29(2): 389-96. https://dx.doi.org/10.1007/s40199-021-00424-6.
Chae Y.K., Arya A., Malecek M.K., Shin D.S., Carneiro B., Chandra S. et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016; 7(26): 40767-80. https://dx.doi.org/10.18632/oncotarget.8194.
Кравченко Е.Н., Набока М.В. Лечение диффузных доброкачественных заболеваний молочной железы. Акушерство и гинекология. 2023; 2: 140-5. [Kravchenko E.N., Naboka M.V. Treatment for diffuse benign breast diseases. Obstetrics and Gynecology. 2023; (2): 140-5. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.25.
Киселев В.И., Сметник В.П., Сутурина Л.В., Селиванов С.П., Рудакова Е.Б., Рахматуллина И.Р., Андреева Е.Н., Фадеева Н.И., Хасанов Р.Ш., Кулагина Н.В., Рожкова Н.И., Артымук Н.В., Гависова А.А., Муйжнек Е.Л., Кузнецов И.Н., Друх В.М. Индолкарбинол (Индинол Форто) – метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология. 2013; 7: 56-62. [Kiselev V.I., Smetnik V.P., Suturina L.V., Selivanov S.P., Rudakova E.B., Rakhmatullina I.R., Andreyeva E.N., Fadeyeva N.I., Khasanov R.Sh., Kulagina N.V., Rozhkova N.I., Artymuk N.V., Gavisova A.A., Muizhnek E.L., Kuznetsov I.N., Drukh V.M. Indole carbinol (Indinol Forto) is a multitargeted therapy option for cyclic mastodynia. Obstetrics and Gynecology. 2013; (7): 56-62. (in Russian)].
Mokbel K., Mokbel K. Harnessing micronutrient power: vitamins, antioxidants and probiotics in breast cancer prevention. Anticancer Res. 2024; 44(6): 2287-95. https://dx.doi.org/10.21873/anticanres.17036.
Reyes-Hernández O.D., Figueroa-González G., Quintas-Granados L.I., Gutiérrez-Ruíz S.C., Hernández-Parra H., Romero-Montero A. et al. 3,3'-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways. Cancer Cell. Int. 2023; 23(1): 180. https://dx.doi.org/10.1186/s12935-023-03031-4.
Киселев В.И., Ляшенко А.А. Молекулярные механизмы регуляции гиперпластических процессов. М.: Димитрейд График Групп; 2005. 347 с. [Kiselev V.I., Lyashenko A.A. Molecular mechanisms of regulation of hyperplastic processes. Moscow; 2005. 347 p. (in Russian)].
Russo E., Grondona C., Brullo C., Spallarossa A., Villa C. et al. Indole antitumor agents in nanotechnology formulations: an overview. Pharmaceutics. 2023; 15(7): 1815. https://dx.doi.org/10.3390/pharmaceutics15071815.
Karimabad M.N., Mahmoodi M., Jafarzadeh A., Darekordi A., Hajizadeh M.R., Hassanshahi G. Molecular targets, anti-cancer properties and potency of synthetic indole-3-carbinol derivatives. Mini Rev. Med. Chem. 2019; 19(7): 540-54. https://dx.doi.org/10.2174/1389557518666181116120145.
Ahmad A., Sakr W.A., Rahman K.M. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr. Drug Targets. 2010; 11(6): 652-66. https://dx.doi.org/10.2174/138945010791170923.
Baez-Gonzalez A.S., Carrazco-Carrillo J.A., Figueroa-Gonzalez G., Quintas-Granados L.I., Padilla-Benavides T., Reyes-Hernandez O.D. Functional effect of indole-3 carbinol in the viability and invasive properties of cultured cancer cells. Biochem. Biophys. Rep. 2023; 35: 101492. https://dx.doi.org/10.1016/j.bbrep.2023.101492.
Peng L., Zhu X., Wang C., Jiang Q., Yu S., Song G. et al. Indole-3-carbinol (I3C) reduces apoptosis and improves neurological function after cerebral ischemia-reperfusion injury by modulating microglia inflammation. Sci. Rep. 2024; 14(1): 3145. https://dx.doi.org/10.1038/s41598-024-53636-6.
Singh A.A., Yadav D., Khan F., Song M. Indole-3-Carbinol and its derivatives as neuroprotective modulators. Brain Sci. 2024; 14(7): 674. https://dx.doi.org/10.3390/brainsci14070674.
Ашрафян Л.А., Рожкова Н.И., Прокопенко С.П., Меских Е.В., Артымук Н.В., Белоцерковцева Л.Д., Долгушина В.Ф., Коротких Н.В., Кузнецова Л.В., Кукарская И.И., Кононенко Т.С., Марочко Т.Ю., Соколов К.А., Вербицкая Ю.С. Влияние препарата индолкарбинола на течение циклической масталгии на фоне доброкачественной дисплазии молочной железы в условиях рутинной клинической практики (исследование «АФРОДИТА»). Акушерство и гинекология. 2024; 2: 134-42. [Ashrafyan L.A., Rozhkova N.I., Prokopenko S.P., Meskikh E.V., Artymuk N.V., Belotserkovtseva L.D., Dolgushina V.F., Korotkikh N.V., Kuznetsova L.V., Kukarskaya I.I., Kononenko T.S., Marochko T.Yu., Sokolov K.A., Verbitskaya Yu.S. The effect of the indolcarbinol on cyclic mastalgia in benign mammary dysplasia in routine clinical practice (“APHRODITE” study). Obstetrics and Gynecology. 2024; (2): 134-42 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.35.
Леваков С.А., Кавиладзе М.Г., Гелашвили А.З. Эффективность применения препарата Индинол Форто у пациенток с дисгормональными заболеваниями молочных желез. Фармакология & Фармакотерапия. 2022; (1): 90-4. [Levakov S.A., Kaviladze M.G., Gelashvili A.Z. The effectiveness of the drug Indinol Forto in patients with dyshormonal diseases of the mammary glands. Pharmacology & Pharmacotherapy. 2022; (1): 90-4. (in Russian)]. https://dx.doi.org/10.46393/ 27132129_2022_1_90.
Общая характеристика лекарственного препарата Индинол Форто. ЛП-N=(007558)-(РГ-RU) от 05.11.2024. [General characteristics of the drug Indinol Forto. LP-N=(007558)-(RG-RU) dated 05.11.2024 (in Russian)].

Received 03.02.2025

Accepted 10.02.2025

Svetlana V. Yureneva, Dr. Med. Sci., Professor, Deputy Director for Science of the Institute of Oncogynecology and Mammology, Academician V.I. Kulakov
National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparin str., 4,
syureneva@gmail.com, https://orcid.org/0000-0003-2864-066X
Victoria G. Averkova, Researcher at the Institute of Oncogynecology and Mammology, Academician V.I. Kulakov National Medical Research Center for Obstetrics,
Gynecology and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparin str., 4, buch1202@mail.ru, https://orcid.org/0000-0002-8584-5517
Lev A. Ashrafyan, Academician of the Russian Academy of Sciences, Professor, Dr. Med. Sci., Head of the Institute of Oncogynecology and Mammology,
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia,
117997, Russia, Moscow, Ac. Oparin str., 4, levaa2004@yahoo.com, https://orcid.org/0000-0001-6396-4948

Pathogenetic aspects and current trends in the treatment of benign breast dysplasia

Yureneva S.V., Averkova V.G., Ashrafyan L.A.

Keywords

References

About the Authors

Similar Articles